CVC CAPITAL PARTNERS PLC

Discover how CVC Capital’s takeover bid for Kobayashi Pharmaceutical and IPO delays reveal hidden valuation risks, governance gaps, and investor‑impact insights.

How CVC’s potential sale of De Oléo could reshape the EU olive‑oil market and what it means for cross‑border ownership in food and beverage.

Explore how CVC-backed IPOs and consumer‑tissue spin‑offs reshape finance amid tightening yields, rising energy costs, and private‑equity exit trends.

Learn how CVC Capital Partners’ interim cash dividend boosts shareholder value, signals financial stability, and sets a new private‑equity income trend.

How CVC Capital’s stake in ABG fuels a new wave of brand‑backed financing for Aston Martin, redefining risk, return, and strategy for institutional investors.

See how CVC Capital’s first‑half 2026 results beat expectations and why it’s weighing a $500‑$600M sale of Yikang Pharmaceutical, revealing its sharp portfolio‑rebalancing strategy.

CVC Capital Partners eyes sale of China’s Yikang Pharmaceutical, a 1,700‑store online‑to‑offline pharmacy chain, sparking investor interest in the regional healthcare market.

Explore how CVC Capital Partners’ co‑control deal with a Middle‑Eastern sovereign wealth fund will delist a leading rare‑disease pharma, boost R&D, and reshape the market.

See how CVC Capital’s takeover of Malaysia’s AHAM Asset Management drives its dual‑sector strategy, unlocking fintech growth and ESG‑aligned returns.

Discover how CVC Capital Partners’ acquisition of IFF’s food‑ingredients division reshapes private‑equity strategy, ESG goals, and market growth in the ingredient sector.